A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Medium urgency

Ozempic Costs to Be Capped in Maryland After Drug Board Vote (1) - Bloomberg Law News

Detected August 28, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

Maryland's drug board voted to cap the cost of Ozempic, a GLP-1 diabetes drug, in the state.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that manufacture or distribute Ozempic (semaglutide) or its equivalents in Maryland. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

Maryland has voted to impose a cost cap on Ozempic, likely affecting pricing and reimbursement for the drug in the state.

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that manufacture or distribute Ozempic (semaglutide) or its equivalents in Maryland.

What you must do

Review current Maryland pricing and reimbursement contracts for Ozempic to assess impact and prepare for potential price adjustments.

Deadline

Not specified in the provided text.

Source: https://news.google.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?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)